Region: Asia | Target Audience: Neurologists and Psychiatrists

This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.

RELEASED DATE: March 19, 2026
EXPIRATION DATE: March 19, 2027

Region: United States | Target Audience: Neurologists and Psychiatrists

This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.

RELEASED DATE: March 19, 2026
EXPIRATION DATE: March 19, 2027

Region: Europe | Target Audience: Neurologist and Psychiatrists

This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.

RELEASED DATE: March 19, 2026
EXPIRATION DATE: March 19, 2027

This case-based educational enduring activity is designed to help Alzheimer’s disease and dementia healthcare providers optimize the use of anti-amyloid therapy for early Alzheimer’s disease. Through interactive case-based learning, our faculty will assist learners in developing strategies to improve multidisciplinary and clinician/patient communication skills to facilitate the best possible treatment outcomes.

RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026

This case-based educational activity is designed to help Alzheimer’s disease and dementia providers diagnose AD earlier in the disease course through comprehensive history and physical, validated cognitive assessments, neuroimaging, and referral, when appropriate. Through interactive case-based learning, our faculty will assist learners in developing strategies to improve multidisciplinary care and clinician/patient communication to facilitate the best possible treatment outcomes.

RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026

This two-part case-based educational grand rounds activity is designed to enhance the capabilities of healthcare providers in managing Alzheimer’s disease and related dementias. Part one focuses on early diagnosis of AD through comprehensive history and physical examinations, quantitative assessments, neuroimaging, and appropriate referrals.

RELEASED DATE: October 31, 2025
EXPIRATION DATE: October 31, 2026

This two-part case-based educational grand rounds activity is designed to enhance the capabilities of healthcare providers in managing Alzheimer’s disease and related dementias. Part two will equip learners with strategies to optimize the use of amyloid-targeting therapies and improve multidisciplinary collaboration and clinician-patient communication to achieve the best possible treatment outcomes.

RELEASED DATE: November 12, 2025
EXPIRATION DATE: November 12, 2026

This enduring activity is designed to offer multidisciplinary expert perspectives on the early identification of mild cognitive impairment (MCI) associated with Alzheimer’s disease (AD), appropriate patient referral, as well as treatment individualization for AD, focusing on disease-modifying therapies and their application to patient care. Through expert pearls and interactive case-based discussions, this series will highlight key considerations across both primary and specialty care in order to optimize multidisciplinary collaboration and patient outcomes throughout the care continuum.

RELEASED DATE: June 01, 2025
EXPIRATION DATE: June 01, 2026

This case-based educational activity is designed to enable providers who manage patients with Alzheimer's disease (AD) to more effectively diagnose mild cognitive impairment (MCI) due to AD. Expert faculty will review updated criteria for screening, diagnosis, and staging; outline best practices for patient evaluation, including medical history and cognitive and diagnostic screening tools; and provide guidance on when to refer patients to specialists. Employing an interactive case-based learning platform, our faculty will assist learners with developing strategies to improve multidisciplinary and clinician/patient communication for shared decision making.

RELEASED DATE: June 30, 2025
EXPIRATION DATE: June 30, 2026

This program has been developed to educate health care practitioners who care for patients with Alzheimer’s disease on the importance of early diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease, timely specialist referral, and effective treatment and monitoring of patients receiving anti-amyloid therapies. It highlights the importance of a multidisciplinary, shared decision-making approach to optimize care management. This Day in the Life docuseries provides unique insights into the patient’s journey from diagnosis to treatment and the physician’s perspective on the clinical strategies for managing disease symptoms.

RELEASED DATE: July 25, 2025
EXPIRATION DATE: July 25, 2026